Landmark Minnesota legislation that will impose $20 million in annual fees on opioid manufacturers and wholesalers to help communities devastated by the ongoing opioid crisis is headed to Gov. Tim Walz (D), who is expected to sign it.
The Minnesota Senate approved May 20 a bill that increases dramatically fees on drug manufacturers and wholesalers doing business in the state. Companies facing the fees include Purdue Pharma LP, Insys Therapeutics Inc., Johnson & Johnson, and Teva Pharmaceuticals USA Inc. The fees will drop if the state benefits financially from ongoing opioid litigation. No other state has approved legislation creating a...
For more stories, analysis and expertiseOR Request Trial
(Updates with additional reporting throughout)